Lixisenatide: difference between revisions
Diff·revision 1 → 2·16:53, 11 Oct 2024
Difference between revision 1 and revision 2 of Lixisenatide. 5 lines changed; the page grew by 581 bytes.
| Revision 1 — 00:25, 8 Oct 2024 ColdChainCleo (talk) start article on the compound 1,190 bytes +1,190 | Revision 2 — 16:53, 11 Oct 2024 HOMA_Hettie (talk) correct the molar mass — source gives the free-base figure, we had the salt 1,771 bytes +581 | ||
|---|---|---|---|
| 11 | Its pharmacological profile emphasises postprandial glycaemic control through pronounced delay of [[Gastric emptying|gastric emptying]], an effect that does not attenuate as it does with continuously present long-acting agonists.{{r|drucker2018}} | 11 | Its pharmacological profile emphasises postprandial glycaemic control through pronounced delay of [[Gastric emptying|gastric emptying]], an effect that does not attenuate as it does with continuously present long-acting agonists.{{r|drucker2018}} |
| 12 | 12 | ||
| + | 13 | == Pharmacology == | |
| + | 14 | Like exenatide, lixisenatide carries glycine at position 2 of the exendin scaffold and is therefore not a substrate for [[Dipeptidyl peptidase-4|DPP-4]]. Its half-life of about three hours nonetheless requires daily dosing, since renal clearance dominates once proteolysis is removed.{{r|drucker2018}} | |
| + | 15 | ||
| + | 16 | The short exposure profile produces a large gastric-emptying effect at each dose, and it is this rather than a large fasting-glucose effect that drives its glycaemic action. Its effect on glycated haemoglobin is modest by current standards.{{r|pfeffer2015}} | |
| + | 17 | ||
| 13 | == References == | 18 | == References == |
| 14 | {{reflist}} | 19 | {{reflist}} |